House to People Living with HIV, HCV and TB: “Drop Dead”
Statement condemning passage of the American Health Care Act (AHCA) today by the House of Representatives and calls for critical community action as the dangerous bill now heads to Senate.
Health Affairs Blog Post Highlights Fair Pricing Coalition Recommendations to Modernize and Strengthen Existing Laws to Control Drug Costs
With growing bipartisan support for feasible measures to control skyrocketing prescription medication costs, a Health Affairs Blog post published today describes four proposals to strengthen and modernize cost control measures that already exist in the United States.
HIV, TB, HCV, Global Health and Research Communities Call on Congress to Protect the Fogarty International Center
Dear Majority Leader McConnell, Minority Leader Schumer, Speaker Ryan, and Democratic Leader Pelosi: We the undersigned urge Congress to reject devastating funding cuts to the National Institutes of Health (NIH) proposed under the President’s Fiscal Year (FY) 2018 “skinny budget,” released on March 16, 2017. Of grave concern is the targeted elimination of the Fogarty International Center at NIH. This indiscriminate cut jeopardizes life-saving research required to end devastating global diseases like tuberculosis (TB) and HIV/AIDS, as well as malaria, dengue, and Ebola.
Mark Harrington’s keynote speech at the Critical Path to TB Drug Regimens meeting
March 20, 2017 – Mark Harrington, TAG's executive director, included in his keynote speech at the Critical Path to TB Drug Regimens meeting the importance of public and private sector funding for research, of thoughtful regulatory strategies, and of rapid uptake of…
No Time to Lose: G20 Leaders Must Fund R&D to End TB
In advance of World TB Day, Treatment Action Group (TAG), Health GAP, AIDS-Free World and Treatment Action Campaign (TAC) urge G20 member states to commit by the July 7, 2017 G20 summit to increase annual funding contributions to USD $1.17 billion for research and development (R&D) to set us on the path to end tuberculosis (TB).
No Time to Lose: G20 Leadership in TB Research Needed to End TB
March 2017--Tuberculosis (TB) is the leading infectious cause of death, and drug-resistant forms of TB account for one in three deaths from antimicrobial resistance. TB research has received scant resources, limiting the possibility of developing the new diagnostic, treatment, and prevention…
President’s Budget Blueprint Threatens Research Essential to End the Epidemics of HIV/AIDS, Tuberculosis, and Hepatitis C Virus
TAG strongly opposses the President’s 2018 budget blueprint, which threatens research essential to ending the epidemics of HIV/AIDS, tuberculosis (TB), and hepatitis C virus (HCV) in the United States and globally by cutting funding and eliminating programs.
LAM PEPFAR Request
February 8, 2017: TAG and partner organizations advocating for the rights of people affected by HIV and TB around the world encouraged the President’s Emergency Plan for AIDS Relief (PEPFAR) to support the immediate introduction of the LAM test in all PEPFAR-funded…
Public Health Groups Welcome Johns Hopkins University and Medicines Patent Pool Agreement for Development of Promising New TB Drug
Public health groups welcomed today’s announcement by Johns Hopkins University (JHU) and the Medicines Patent Pool (MPP) of an agreement that could expedite the research and development of a promising tuberculosis drug and lead to improved treatment options for people living with TB.
2016 TAG Update
TAG's annual review of progress we've made on the the fight to end HIV/AIDS, Viral Hepatitis, and Tuberculosis.